| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC0480 |
| Trial ID | NCT03935893 |
| Disease | Neuroendocrine Tumor | Pancreatic Cancer | Mesothelioma | Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcoma | Colorectal Cancer | Stomach Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KRAS G12D TCR-T cells |
| HLA | HLA-C*08:02 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers |
| Year | 2019 |
| Country | United States |
| Company sponsor | Udai Kammula |
| Other ID(s) | 19-004 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||